Following the LEADER – why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes
References (19)
- et al.
Effects of intensive blood-pressure control in type 2 diabetes mellitus
The New England Journal of Medicine
(2010) - et al.
Glucose control and vascular complications in veterans with type 2 diabetes
The New England Journal of Medicine
(2009) - et al.
Effects of intensive glucose lowering in type 2 diabetes
The New England Journal of Medicine
(2008) - et al.
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The New England Journal of Medicine
(2011) - et al.
Effects of combination lipid therapy in type 2 diabetes mellitus
The New England Journal of Medicine
(2010) - et al.
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
The New England Journal of Medicine
(2015) - et al.
Sitagliptin and cardiovascular outcomes in type 2 diabetes
The New England Journal of Medicine
(2015) - et al.
10-year follow-up of intensive glucose control in type 2 diabetes
The New England Journal of Medicine
(2008) - et al.
Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care
(2015)
There are more references available in the full text version of this article.
Cited by (0)
Conflict of interest: Dr. Kosiborod has received research grants from Astra Zeneca, Gilead Sciences, Genentech and Sanofi, has served as consultant for AstraZeneca, Ely Lilly, Takeda, Amgen, Sanofi, GSK, Boehringer Ingelheim, Novo Nordisk, Merck (Diabetes), ZS Pharma, and Glytec, and participated in speakers bureau for Amgen.
© 2016 Elsevier Inc. All rights reserved.